PETCH-TIKVA, ISRAEL--(Marketwire - July 23, 2008) - NST NeuroSurvival Technologies Ltd. (NST), a clinical phase company developing molecular imaging agents and drugs that identify and target cells undergoing apoptosis (programmed cell death), today announced that the U.S. Food and Drug Administration (FDA) issued a “safe to proceed” letter for the company’s APOSENSE® [18F]-ML-10 Investigational New Drug Application (IND).
